UBS initiated coverage of Omega Healthcare (OHI) with a Buy rating and $50 price target The firm expects positive estimate revisions for the company, driven by better than expected future investment volumes and strong EBITDAR coverage. Omega should see upside to investment volumes, driven by a “broad” investment total addressable market, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OHI:
- Omega Healthcare: Strong Buy Rating Driven by Strategic Investments and Positive Market Trends
- Omega Healthcare price target raised to $48 from $46 at BofA
- Omega Healthcare price target raised to $45 from $42 at Scotiabank
- Omega Healthcare price target raised to $50 from $45 at Citi
- Omega Healthcare Investors Reports Strong Q3 2025 Earnings